Quest Diagnostics reports Haystack results and Quest Diagnostics stock costs EUR 206.40

Published on 10/06/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haystack MRD showed 100.00 percent specificity on October 1, 2026. Quest Diagnostics stock trades at EUR 206.40 on October 6, 2026, before results October 22.

Makroaufnahme einer Laborzentrifuge mit Blutproben-Röhrchen und sichtbarer Plasmatrennung — Quest Diagnostics US74834L1008 fängt Makroaufnahme rotierender Zentrifuge mit getrennten Blutproben-Schichten in Röhrchen dramatisch ein, Illustration mit AI erstellt.

Quest Diagnostics (ISIN US74834L1008) was trading at EUR 206.40 at Lang & Schwarz on October 6, 2026 at 10:16 a.m. CEST, while a new Haystack MRD study published on October 1, 2026 showed 100.00 percent specificity at both 3-year and 5-year follow-up. Yahoo Finance reported that the test reached 100.00 percent sensitivity at 3 years and 83.30 percent at 5 years.

Haystack widens the oncology case

The study compared Haystack MRD with carcinoembryonic antigen, a standard blood biomarker. Haystack detected recurrence with 88.90 percent sensitivity versus 11.10 percent for the comparator after a median follow-up of 60 months, giving Quest a concrete performance point as it expands its oncology diagnostics portfolio.

The test also detected circulating tumor DNA across 27 solid tumor types in a real-world cohort, with 42.00 percent of positive results below 0.5 mean ctDNA molecules per milliliter. Quest said Haystack is authorized for patient access in all 50 U.S. states, according to the Yahoo Finance release.

Revenue growth meets a margin tradeoff

In the second quarter of 2026, Quest Diagnostics generated USD 3.04 billion in revenue, up 10.20 percent from the same quarter of 2025. Adjusted earnings per share rose 19.10 percent year over year to USD 3.12, while reported operating margin was 15.10 percent versus 15.90 percent in the prior-year quarter, according to the Yahoo Finance earnings-call transcript.

Management raised fiscal 2026 guidance to USD 11.95 billion-USD 12.05 billion in revenue and USD 11.05-11.25 in adjusted earnings per share. The same transcript said cash from operations reached USD 875 million through the second quarter, compared with USD 858 million in the year-earlier period.

Analyst target and results date

MarketScreener reported on September 21, 2026 that Truist raised its Quest Diagnostics price target from USD 250.00 to USD 260.00 while maintaining a Hold rating. The target change gives investors a defined valuation reference, but the USD target cannot be combined with the euro quote.

Quest Diagnostics will release third-quarter 2026 results before the U.S. market opens on October 22, 2026, with its conference call scheduled for 8:30 a.m. Eastern Time, according to the company's investor-relations release dated September 22, 2026.

Quest Diagnostics stock stays data-led

Quest Diagnostics stock was trading at EUR 206.40 at Lang & Schwarz on October 6, 2026 at 10:16 a.m. CEST. The company combines a fresh oncology evidence point with double-digit second-quarter revenue growth, while the next earnings release supplies the next dated test of its fiscal 2026 guidance. The further course of trading is shown by the continuously updated real-time quote of Quest Diagnostics stock.